Ponesimod not checked
Vanda Pharmaceuticals · Actelion · ACT-128800 · VSP-128
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total · 1 in the EU
What this is
- How it works
- Sphingosine 1-phosphate Receptor Modulator FDA class
- How it’s given
- “Ponesimod administered orally once daily. Participants are randomized 2:1 to Ponesimod or placebo during a 16-week double-blind period. A 14-day titration is followed by a stable dose daily from Day 15 through end of treatment. Participants may enter a 36-week open-label extension receiving Ponesimod.”In the company’s words, NCT07686081 on ClinicalTrials.gov
- Main trialPhase 3
- “An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis”In the company’s words, NCT07362017 on ClinicalTrials.gov
- Other names
- ACT-128800 · VSP-128
Other drugs for Moderate-to-severe Chronic Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up2
- Aug 2028Phase 3 trial completes · ClinicalTrials.gov
- Apr 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2028 | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis | |
| Phase 3Recruiting | Apr 2029 | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Completed | 1 Jun 2011 | Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis | |
| Phase 2Completed | 31 Oct 2012 | ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026